TriaGen Wealth Management LLC Purchases Shares of 11,480 Gilead Sciences, Inc. $GILD

TriaGen Wealth Management LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 11,480 shares of the biopharmaceutical company’s stock, valued at approximately $1,274,000.

Several other hedge funds have also modified their holdings of the company. Daymark Wealth Partners LLC increased its holdings in shares of Gilead Sciences by 7.3% in the 3rd quarter. Daymark Wealth Partners LLC now owns 31,174 shares of the biopharmaceutical company’s stock worth $3,460,000 after buying an additional 2,114 shares during the last quarter. Railway Pension Investments Ltd lifted its holdings in Gilead Sciences by 3.1% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after buying an additional 42,200 shares in the last quarter. Earned Wealth Advisors LLC increased its position in shares of Gilead Sciences by 3.5% during the third quarter. Earned Wealth Advisors LLC now owns 5,322 shares of the biopharmaceutical company’s stock worth $591,000 after acquiring an additional 179 shares during the period. Asset Management One Co. Ltd. raised its stake in shares of Gilead Sciences by 1.9% during the third quarter. Asset Management One Co. Ltd. now owns 727,196 shares of the biopharmaceutical company’s stock valued at $80,719,000 after acquiring an additional 13,719 shares in the last quarter. Finally, Gateway Investment Advisers LLC boosted its holdings in shares of Gilead Sciences by 57.7% in the third quarter. Gateway Investment Advisers LLC now owns 119,323 shares of the biopharmaceutical company’s stock valued at $13,245,000 after purchasing an additional 43,672 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently weighed in on GILD shares. TD Cowen lifted their price objective on Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. Daiwa Capital Markets increased their price objective on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Finally, Mizuho upped their target price on Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $131.68.

Insider Activity

In related news, Director Kelly A. Kramer sold 2,805 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the transaction, the director directly owned 1,339 shares in the company, valued at approximately $170,186.90. This trade represents a 67.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the transaction, the director directly owned 8,920 shares of the company’s stock, valued at $1,115,713.60. The trade was a 35.92% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 136,257 shares of company stock valued at $16,855,192 over the last 90 days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $121.60 on Monday. Gilead Sciences, Inc. has a 52 week low of $88.57 and a 52 week high of $128.70. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The firm has a market cap of $150.87 billion, a P/E ratio of 18.85, a P/E/G ratio of 0.65 and a beta of 0.33. The business’s 50 day moving average price is $123.05 and its 200 day moving average price is $117.17.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the prior year, the firm earned $2.02 EPS. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were paid a $0.79 dividend. The ex-dividend date was Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. Gilead Sciences’s dividend payout ratio is presently 48.99%.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.